 | |
| Clinical data | |
|---|---|
| Trade names | Acelex |
| Other names | CG100649 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H16FNO4S |
| Molar mass | 361.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Polmacoxib (trade nameAcelex) is anonsteroidal anti-inflammatory drug (NSAID) used to treatosteoarthritis. It was developed asCG100649 and approved for use in South Korea in February 2015.[1] It inhibits the enzymescarbonic anhydrase andCOX-2.A study in healthy volunteers showed drug effects on urinaryprostaglandin metabolites for both polmacoxib andcelecoxib that suggest a similar cardiovascular risk profile.[2] Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies.[3]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |
